X4 Pharmaceuticals, Inc. (XFOR), Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia (CN).
A Phase 3 study of mavorixafor in certain primary CN conditions is underway. Topline data from Phase 3 4WARD study in CN are expected in late 2026.
Mavorixafor is already approved in 2024 for the treatment of WHIM syndrome, a rare genetic disorder.
For comments and feedback: editorial@rttnews.com